EGRIFTA® (tesamorelin for injection) is approved in Canada for the reduction of excess abdominal fat in people living with HIV who have lipodystrophy.
Lipodystrophy affects the redistribution of fat that includes the accumulation and loss of fat in certain parts of the human body. The excess fat in the abdomen exerts pressure in the abdomen in the internal organs. The consequences of lipodystrophy are therefore numerous and serious.
It is estimated that 15% of people living with HIV in Canada also have lipodystrophy.
It is important to note that lipodystrophy has nothing to do with the subcutaneous fat found in obese people.
EGRIFTA® is no longer available in the United States. Only EGRIFTA SV® is available in the United States.